跳至正文
OpenAgentSkill
浏览已开放 · 目录记录日期 2026-11-21 · 自动更新和账户服务暂时关闭。
浏览器与自动化

pipeline-medicines

Medicines pipeline analysis over structured universes: Phase I-III assets with probability-of-success discipline (unadjusted peak x POS = modeled value; POS changes logged with reasons), trial status-diff tracking, and mechanism/competitor mapping via drug-knowledge lookups.

agentii-ai · 已有静态检查记录

安装与使用

运行命令前先阅读来源与依赖说明。复制命令不会自动安装或执行。

npx skills add agentii-ai/agentii-investment-intelligence --skill pipeline-medicines

技能说明


name: pipeline-medicines description: "Medicines pipeline analysis over structured universes: Phase I-III assets with probability-of-success discipline (unadjusted peak x POS = modeled value; POS changes logged with reasons), trial status-diff tracking, and mechanism/competitor mapping via drug-knowledge lookups." sectors: [med.medicines_biotech, med.medical_devices] multi_ticker_semantics: single_target temporal_scope: default_quarters: 8 max_quarters: 20 description: "Long-horizon pipeline window default 8 quarters; up to 20 for multi-year development programs." allowed_tools:

  • get_company_drugs
  • search_universe_drugs
  • search_drug_knowledge
  • get_drug_knowledge
  • search_drugs_by_target
  • search_drugs_by_indication
  • search_clinical_trials
  • get_clinical_trial
  • search_fda_approvals
  • search_companies
  • get_company_profile
  • search_earnings_calendar
  • search_investment_cases
  • search_knowledge_entries retrieval_scope: structured_only min_tool_diversity: 3 parameter_free: false

Methodology inspired by publicly taught pipeline-valuation frameworks; all text is an original paraphrase.

Defaults

ParameterDefault ValueRationale
asset_scopeall disclosed assetsFull-pipeline enumeration first
pos_sourcepublished phase transition rangesStarting point, then adjusted with logged reasons
status_difftruePrevious vs current trial status shown per asset
competitor_maptrueSame-target and same-indication crowding surfaced
value_framerisk-adjustedModeled value = unadjusted peak x POS, both shown

Preflight

Run canonical pre-flight per contracts/preflight.md. Propagate X-Agentii-Trace per contracts/x-agentii-trace-header.md. Confirm ticker resolution via search_companies before asset queries.

Triggers

  • "Analyze [ticker]'s drug pipeline by phase."
  • "What are the Phase II and III assets for [ticker]?"
  • "Risk-adjust [ticker]'s pipeline with explicit POS assumptions."
  • "Which of [ticker]'s programs is most valuable?"
  • "What trials recently changed status for [ticker]?"
  • "Who else is targeting [mechanism/target]?"
  • "How crowded is [indication], and what does that mean for [ticker]?"
  • "Log every POS change with reasons for [ticker]'s pipeline."
  • "What is the next catalyst for each of [ticker]'s assets?"
  • "Compare [ticker]'s pipeline against same-indication competitors."
  • "Map [ticker]'s assets by mechanism of action."
  • "What does [ticker]'s pipeline say about its runway?"

Production Grounding

  • POS discipline: every asset carries an unadjusted peak sales estimate and a phase-appropriate POS; the modeled number is peak x POS, never a bare risk-adjusted figure. Every POS change is logged with its reason (trial data, competitor data, discontinuation) — silent POS drift is a defect.
  • Phase ladder: Phase I safety/dosing, Phase II efficacy signal, Phase III registrational; option value rises with phase. Apply scrutiny axes when sizing pivotal assets.
  • Status-diff discipline: show previous vs current status per trial (New/Suspended/Terminated/Ahead/Delayed/...); Terminated plus enrollment collapse is a red flag; recruitment-complete starts the readout clock.
  • Competitor mapping: same-target and same-indication crowding discounts peak sales, not just POS; mechanism overlap explains class risk.
  • Grounding detail lives in references/knowledge-frameworks.md.

Data Source Priority

  1. get_company_drugs / search_universe_drugs — asset inventory from the med universe.
  2. search_drug_knowledge / get_drug_knowledge — mechanism, targets, indications, phase per drug.
  3. search_drugs_by_target / search_drugs_by_indication — reverse lookups for the competitor map.
  4. search_clinical_trials / get_clinical_trial — status, enrollment, primary-completion dates.
  5. search_fda_approvals — registration history; search_earnings_calendar for timing; knowledge layer via search_investment_cases / search_knowledge_entries.

Methodology

Retrieval Scope

structured_only

Retrieval Strategy

  1. Pull asset inventory (get_company_drugs), then universe cross-checks (search_universe_drugs).
  2. Enrich per asset from search_drug_knowledge / get_drug_knowledge (mechanism, targets, phase).
  3. Pull trial records (search_clinical_trials) for status-diff and next-catalyst dates.
  4. Build the competitor map via search_drugs_by_target / search_drugs_by_indication.
  5. Size each asset (peak x POS with change log); ground in cases and knowledge entries.

Temporal Scope

See frontmatter temporal_scope block. Development programs span years; status history may reach back 8-12 quarters.

Tool Allowlist

See frontmatter allowed_tools.

Protocol

  1. Asset enumeration
  2. Phase and mechanism enrichment
  3. Status-diff and catalyst dating
  4. Competitor map assembly
  5. POS model with change log

Modes

  • Phase scan (default): all assets by phase with status-diff and next catalyst.
  • POS model: peak x POS modeling with a full change log and scenario brackets.
  • Competitor map: target/indication crowding with class-risk read.

Tool Fallbacks

FailureFallback
get_company_drugs emptysearch_universe_drugs by company or indication; annotate coverage_gap
Drug-knowledge record missingFlag mechanism/competitor data unavailable; never infer targets
No trial rowsMark status undisclosed; note the readout clock is unverified
Knowledge tools emptyProceed with structured data only

Output File

{ticker}/{YYYY-MM-DD_HHMM}_pipeline-medicines_{affix}.md

Output Structure

  1. Executive Summary — pipeline stance in 2-3 sentences
  2. Asset Table — phase, indication, mechanism, status-diff, next catalyst
  3. POS Model — unadjusted peak, POS, modeled value per asset, change log with reasons
  4. Competitor Map — same-target and same-indication crowdi
阅读完整来源 ↗